KBI Biopharma Signed an Agreement with Oragenics to Support Development of the Intranasal COVID-19 Vaccine Candidate NT-CoV 2 -1
Corporate
KBI Biopharma, Inc. (“KBI“), a life sciences group company of JSR Corporation, announced that it has entered into an agreement with Oragenics, Inc. (NYSE American: OGEN, “Orgenics”) on March 7, 2022, for process transfer, process optimization and cGMP manufacturing of NT-CoV 2 -1, Orgagenics’ intranasal vaccine candidate expressed in a proprietary CHO cell line.
Under this agreement, KBI will supply material for phase 2 clinical trial of Oragenics’ intranasal COVID-19 vaccine candidate, as well as the upstream/downstream process transfer and optimization, and the analytical method development.
For more information, please visit the KBI’s release page below.